Table 3 Comparison of characteristics of FUBC and No-FUBC

Age, median (IQR)

64 (54–75)

65 (55–77)

0.395

64 (51–75)

65 (53.5–76)

0.385

Male sex, n (%)

319 (56.6)

139 (56)

0.892

130 (55.1)

131 (55.5)

0.926

Comorbidities, n (%)

Diabetes mellitus

163 (28.9)

74 (29.8)

0.787

54 (22.9)

71 (30.1)

0.076

Hypertension

234 (41.5)

96 (38.7)

0.458

96 (40.7)

94 (39.8)

0.851

Chronic renal Failure

86 (15.2)

38 (15.3)

0.978

33 (14.0)

35 (14.8)

0.793

Coronary artery disease

119 (21.1)

47 (19)

0.485

50 (21.2)

44 (18.6)

0.489

Cardiac failure

57 (10.)

24 (9.7)

0.851

19 (8.1)

22 (9.3

0.624

Cerebrovascular disease

66 (11.7)

30 (12.1)

0.873

31 (13.1)

29 (12.3)

0.782

Chronic pulmonary disease

58 (10.3)

26 (10.5)

0.931

24 (10.2)

26 (11.0)

0.765

Malignancy

264 (46.8)

120 (48.4)

0.678

128 (54.2)

116 (49.2)

0.269

CCI(n), median (IQR)

5 (3–7)

5 (3–7)

0.250

5 (3–7)

5 (3–7)

0.481

Clinical severity at index blood culture time, median(IQR)

SOFA

4 (2–6)

4 (2–7)

0.011

4 (2–7)

4 (2–7)

0.994

SIRS

2 (1–3)

2 (1–3)

0.161

2 (1–3)

2 (1–3)

0.509

Admission ward, n (%)

ICU

229 (40.6)

128 (51.6)

0.004

111(47.0)

116 (49.2)

0.645

Non-ICU

335 (73.6)

120 (35.9)

125 (53.0)

120 (50.8)

Invasive device, n (%)

Central venous catheter

249 (44.1)

113 (45.)

0.709

168 (71.2)

101 (42.8)

< 0.001

Cardiac device

46 (8.2)

8 (3.2)

0.009

13 (5.5)

7 (3.0)

0.170

Prosthetic device

23 (4.1)

8 (3.2)

0.559

12 (5.1)

8 (3.4)

0.361

Site of BSI acquisition, n (%)

Community-acquired

234 (41.4)

93 (37.5)

0.286

63 (26.7)

91 (38.6)

0.006

Hospital-acquired

330 (58.5)

155 (62.5)

173 (73.3)

145 (61.4)

Source of BSI, n (%)

Primary BSI

244 (43.2)

104 (41.9)

0.725

100 (42.4)

100 (42.4)

1.00

Secondary BSI

320 (56.8)

144 (58.1)

136 (57.6)

136 (57.6)

Skin and soft tissue infection

16 (2.8)

6 (2.4)

5 (2.1)

6 (2.5)

Gastrointestinal tract infection

41(7.3)

20 (8.1)

9 (3.8)

20 (8.5)

Genitourinary tract infection

87 (15.4)

34 (13.7)

16(6.8)

33 (14.0)

Respiratory tract infection

37 (6.6)

29 (11.7)

17 (7.2)

27 (11.4)

Central venous catheter infection

135 (23.9)

55 (22.2)

87 (36.9)

50 (21.2)

Other infection

4 (0.7)

0 (0)

2 (0.8)

0 (0)

Microorganisms in BSI, n (%)

Enterobacterales

377 (66.8)

155 (62.5)

0.230

143 (60.6)

150 (63.6)

0.507

 Escherichia coli

173 (30.7)

74 (29.8)

59 (25.0)

72 (30.6)

 Klebsiella spp.

142 (25.1)

55 (22.2)

62 (26.3)

53 (22.5)

 Enterobacter spp.

35 (6.2)

13 (5.2)

13 (5.5)

12 (5.1)

 Serratia spp.

8 (1.4)

4 (1.6)

3 (1.3)

4 (1.7)

 Proteus spp.

7 (1.2)

5 (2.09)

2 (0.8)

5 (2.1)

 Morganella spp.

5 (0.9)

2 (0.8)

3 (1.3)

2 (0.8)

 Salmonella spp.

5 (0.9)

1 (0.4)

1 (0.4)

1 (0.4)

 Citrobacter spp.

2 (0.4

1 (0.4)

0 (0.0)

1 (0.4)

P. aureginosa

37 (6.6)

24 (9.7)

0.121

16 (6.8)

24 (10.2)

0.186

A.baumannii

50 (8.9)

32 ( 12.9)

0.079

34 (14.4)

28 (11.9)

0.414

S. maltophlia

44 (7.8)

18 (7.3)

0.788

20 (8.5)

216 (6.8)

0.488

Others*

56 (9.9)

19 (7.7)

0.304

23 (9.7)

18 (7.6)

0.414

CR-GN

130 (25.3)

72 (31.4)

0.082

74 (34.7)

65 (29.7)

0.260

MDR

173 (30.7)

83 (32.4)

0.430

73 (47.4)

81 (52.6)

0.432

XDR

76 (13.5)

38 (15.3)

0.485

42 (17.8)

34 (14.4)

0.316

PDR

6 (1.1)

7 (2.8)

0.066

3 (1.3)

6 (2.5)

0.313

Follow-up duration (days), median (IQR)

17 (11–27)

12 (6–24)

< 0.001

17 (11–30)

12 (7–24)

< 0.001

Follow-up duration days in patients without mortality, median (IQR)

18 (13–30)

15.5(9–30)

0.003

21 (15–30)

15 (9–30)

< 0.001